BioSpace News Archive

Applied DNA Sciences, Inc. announced that it has successfully manufactured and shipped its first research use only quantity of self-amplifying mRNA template generated by its Linea™ DNA platform to an unidentified preclinical therapeutic mRNA developer.

Bristol Myers Squibb announced that the U.S. Food and Drug Administration has accepted the supplemental Biologics License Application for Breyanzi to expand its current indication to include the treatment of adult patients with relapsed or refractory chronic lymphocytic leukemia or small lymphocytic lymphoma who received a prior Bruton tyrosine kinase inhibitor and B-cell lymphoma 2 inhibitor.

Vetter, a leading global Contract Development and Manufacturing Organization (CDMO), has received the permanent Manufacturer’s Authorization for its clinical development site in Rankweil, Austria.

Bryn Pharma, LLC announced that positive clinical data supporting use of its epinephrine nasal spray – known as NDS1C – in adults with or without congestion, will be presented during the 2023 American College of Allergy Asthma and Immunology Annual Scientific Meeting.

NanoString Technologies announced it will present at the Society for Neuroscience annual meeting a large body of new brain research powered by its industry-leading digital spatial profiling and spatial imaging platforms.

Certis Oncology Solutions announced it has been selected as “Overall Immunology Company of the Year” in the third annual BioTech Breakthrough Awards program conducted by BioTech Breakthrough, a leading independent market intelligence organization that evaluates and recognizes standout life sciences and biotechnology companies, products and services.

As a pioneer in innovative chaperone technology, SOLA Biosciences Inc. will present its compelling preclinical proof-of-concept data for SOL-257, a targeted gene therapy for misfolded TDP-43 in Amyotrophic Lateral Sclerosis, at Neuroscience 2023 in Washington, D.C. on November 15 and the ALS One Symposium on November 17.

PharmaDrug Inc. (CSE: PHRX) (OTC Pink: LMLLD) (“PharmaDrug” or the “Company”), announces that it has granted a total of 6,250,000 stock options (“Options”) to purchase common shares of the Company to certain officers,

Senseonics Holdings, Inc. today announced plans to participate in the upcoming Stifel 2023 Healthcare Conference, taking place in New York, NY.

DiaMedica Therapeutics Inc. today announced that Rick Pauls, its President and CEO and Dave Wambeke, its Chief Business Officer will be participating in the 14th Annual Craig-Hallum Alpha Select Conference being held in New York on Thursday, November 16, 2023.